Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용희 | - |
dc.date.accessioned | 2018-06-09T08:14:40Z | - |
dc.date.available | 2018-06-09T08:14:40Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0149-5992 | - |
dc.identifier.other | OAK-4711 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/244775 | - |
dc.description.abstract | OBJECTIVE - We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients. RESEARCH DESIGN AND METHODS - This was a randomized, double-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched. Thirty-two patients were given placebo, and 30, 32, 31, and 31 patients were given daily 10, 20, 40, and 80 mg simvastatin, respectively, during a 2-month treatment period. RESULTS - Simvastatin doses of 10, 20, 40, and 80 mg significantly reduced total cholesterol (mean changes 27, 25, 37, and 38%), LDL cholesterol (39, 38, 52, and 54%), and apoli-poprotein B levels (24, 30, 36, and 42%) and improved flow-mediated dilation (FMD) (68, 40, 49, and 63%) after 2 months of therapy compared with baseline (P < 0.001 by paired t test) or compared with placebo (P < 0.001 by ANOVA). Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5, 8, 6, and 6%) compared with baseline (P < 0.05 by paired t test) or compared with placebo (P = 0.011 for adiponectin and P = 0.034 for QUICKI by ANOVA). However, the magnitudes of these percent changes (FMD, adiponectin, and QUICKI) were not significantly different among four different doses of simvastatin despite dose-dependent changes in the reduction of apolipoprotein B levels. CONCLUSIONS - Simvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction. © 2008 by the American Diabetes Association. | - |
dc.language | English | - |
dc.title | Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients | - |
dc.type | Article | - |
dc.relation.issue | 4 | - |
dc.relation.volume | 31 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 776 | - |
dc.relation.lastpage | 782 | - |
dc.relation.journaltitle | Diabetes Care | - |
dc.identifier.doi | 10.2337/dc07-2199 | - |
dc.identifier.wosid | WOS:000254591900029 | - |
dc.identifier.scopusid | 2-s2.0-48649083592 | - |
dc.author.google | Koh K.K. | - |
dc.author.google | Quon M.J. | - |
dc.author.google | Han S.H. | - |
dc.author.google | Lee Y. | - |
dc.author.google | Ahn J.Y. | - |
dc.author.google | Kim S.J. | - |
dc.author.google | Koh Y. | - |
dc.author.google | Shin E.K. | - |
dc.contributor.scopusid | 이용희(35737417000) | - |
dc.date.modifydate | 20211210153745 | - |